Procyon Technologies In The News
Revolutionizing Heart Disease Treatment with iPSC-Derived MSCs
Procyon Technologies was pleased to see the efficacy and viability of the iPSC-derived MSCs over 12 weeks while encapsulated in our proprietary immunoisolation devices. For more information, see https://www.biorxiv.org/search/10.1101%252F2025.04.01.646502. Cynata has...
Procyon Technologies, St. Vincent’s Institute, and Cynata Therapeutics team up on heart repair therapy
A two-year grant from the Medical Research Future Fund’s Cardiovascular Health Mission will support a team led by St. Vincent's Institute for Medical Research to develop a stem cell-based therapy for heart repair. For more information, see ...
Diabetes Cell Therapies Take Evasive Action
Procyon Technologies and Klearchos Papas are mentioned in a Nature Biotechnology article published in Feb 2022
Health Sciences Researchers Close In on Diabetes Solution
After hunting for decades, Drs. Klearchos Papas, Robert Johnson and Tom Loudovaris helped develop a bio-artificial pancreas at the University of Arizona Health Sciences. The team’s solution is composed of islet cells protected in a special oxygen-enabled pouch...
Assessment of Islet Quality Pre-Transplant by Klearchos Papas, Ph.D.
At the invitation and request of the U.S. Food & Drug Administration (FDA), Klearchos Papas, Ph.D., presented on "Assessment of Islet Quality Pre-Transplant" at the advisory committee meeting of the Center for Biologics Evaluation and Research (CBER), Office of...
Procyon Technologies LLC and Novo Nordisk A/S to Collaborate on the Development of a Stem-Cell Based Therapy for Type 1 Diabetes
Procyon Technologies LLC today announced that it has entered into an exclusive research collaboration and license agreement with Novo Nordisk A/S to develop an implantable cell encapsulation device to be used in Novo Nordisk’s development of a novel therapy for Type 1 diabetes.
Type 1 Diabetes Research at the University of Arizona
Dr. Kowalski, JDFR president and CEO, recognized research being done by Dr. Klearchos Papas and Dr. Robert Johnson. Drs. Papas and Johnson are with the University of Arizona in Tucson, and are developing groundbreaking cell therapies to cure T1D through two projects:...
Islet Cell Containing Implantable Device in Development Releases Insulin in Response to Glucose Levels
Unfortunately insulin shots, pens and pumps fail to perfectly manage blood sugar in many children, which may lead to long-term complications. For the last two decades, Dr. Papas has been working on a solution to this problem. In collaboration with other scientists...
Oxygen Critical to Practical Islet Transplants
On April 2, 2019, Insulin Nation published an article about teams from the Universities of Arizona and Minnesota collaborating and on Klearchos Papas, PhD about his oxygen generator-based islet ‘tea bag’ transplant device. See Oxygen Critical to Practical Islet...
Implantable Device in Development Releases Insulin for Children with Diabetes
Dr. Papas and his team developed a technology that allows insulin producing islet cells to be surgically implanted in the body
Procyon is the brightest star in the Canis Minor constellation.
This spectroscopy image was taken by Robert C. Johnson, Ph.D.